The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2016, representing a year-on-year rise of 20.4%. After high growth in 2016, the lot release decelerated in 2017 due to two-invoice system (one invoicing for "from pharmaceutical company to primary dealer", and the other invoicing for "from dealers to hospitals") with full-year quantity standing at 64.29 million bottles, being on a par with the year-ago level.
Human albumin registered lot release volume of 38.95 million bottles and human immunoglobulin (pH4) for intravenous injection 10.07 million bottles in 2017, down 0.9% and 7.5% from a year ago, respectively, largely due to a slow-down in lot release caused by failure of Gansu Institute of Biological Products in disclosing data on lot release volume of blood products and two-invoice system. Meanwhile, the lot release volume of human prothrombin complex, human hepatitis B immunoglobulin (pH4) for intravenous injection, and human rabies immunoglobulin soared by 26.8%, 46.7% and 36.8%, respectively.
There are over 30 blood product manufacturers in a less concentrated industry in China. Among them, China Biologic Products, Hualan Biological Engineering, Shanghai RAAS Blood Products and Beijing Tiantan Biological Products are more competitive, as they have richer blood product lines and adequate supply of raw materials from plasma stations.
In the future, China’s blood product industry will head for the following three aspects:
1. Faster industry integration, higher concentration: over the years, the rising number of M&A cases among Chinese blood product companies gave a boost to industry integration and concentration.
2. Plasma collection volume and number of plasma stations determine position in industry: number of plasma stations has a direct impact on collection volume, and raw material supply of companies directly hinges on collection volume. In current stage, Beijing Tiantan Biological Products Co., Ltd. has completed assets restructuring, and is hopefully to be the bellwether of the industry for it boasts 49 plasma stations, ranking first in the industry.
3. Companies’ more input on research and development of new products is a boon for higher utilization of plasma: Chinese blood product companies are now racing to develop new products, with the aims of stronger comprehensive strength and higher utilization of plasma to reduce waste.
The report highlights the following:
- Analysis on development of China blood product industry, including policies, status quo, market structure, supply & demand, market size and competitive landscape;
- Analysis on market segments of China blood product industry, covering human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor VIII, hepatitis B human immunoglobulin, human immunoglobulin, human prothrombin complex and the like;
- Analysis on 15 blood product enterprises, including operation, revenue structure, gross margin, R & D investment, blood product business and development strategy;
- Summary & forecast and trends.
1. Overview of Blood Products
1.3 Recombinant Blood Products
1.4 Industry Chain
2. Development of China Blood Product Industry
2.1 Related Policies
2.2 Status Quo
2.3 Market Structure
2.4 Market Supply and Demand
2.5 Market Size
2.6 Competition Pattern
3. Market Segments of China Blood Product Industry
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Market Structure
3.1.3 Competition Pattern
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Development Status
3.2.2 Competition Pattern
3.3 Coagulation Factor VIII
3.3.1 Development Status
3.3.2 Competition Pattern
3.4 Hepatitis B Immunoglobulin
3.4.1 Development Status
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Development Status
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Development Status
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Development Status
3.7.2 Competition Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Development Status
3.8.2 Competition Pattern
4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Development Strategy
4.5 Zhenxing Biopharmaceutical & Chemical
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Customers
4.5.6 R&D and Investment
4.5.7 Blood Products Business
4.5.8 Development Strategy
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Blood Products Business
4.6.7 Development Strategy
4.7 Wuhan ZhongyuanRuide Biological Products
4.7.3 Blood Products Business
4.7.4 Development Strategy
4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.8.2 Blood Products Business
4.9 Shanghai Institute of Biological Products
4.9.2 Blood Products Business
4.10 Wuhan Institute of Biological Products Co., Ltd.
4.10.2 Blood Products Business
4.11 Shanxi Kangbao Biological Product
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.2 Blood Products Business
4.13 Beijing Bohui Innovation Technology
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 R&D Investment
4.13.6 Blood Products Business
4.13.7 Hebei Da’an Pharmaceutical
4.13.8 Guangdong Weilun Biological Pharmaceutical
4.14 Weiguang Biological Products
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 R&D Investment
4.14.6 Blood Products Business
4.14.7 Development Strategy
4.15 Nanyue Biopharming Corporation Ltd.
4.15.2 Blood Products Business
5. Summary and Forecast
5.2 Development Trend
5.2.1 Industry Integration Speeds Up, Concentration Rises Further
5.2.2 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.3 Plasma Volume Increases Progressively
5.2.4 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness
5.2.5 Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.6 Downstream Demand Stimulates the Development of the Industry
5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry
- Beijing Bohui Innovation Technology
- Beijing Tiantan Biological Products
- China Biologic Products (CBPO)
- Green Cross China
- Guizhou Taibang Biological Products Co., Ltd.
- Hualan Biological Engineering Co., Ltd.
- Jiangxi Boya Bio-Pharmaceutical
- Nanyue Biopharming Corporation Ltd.
- Shandong Taibang Biological Products Co., Ltd.
- Shanghai Institute of Biological Products
- Shanghai RAAS Blood Products
- Shanxi Kangbao Biological Product
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
- Weiguang Biological Products
- Wuhan Institute of Biological Products Co., Ltd.
- Wuhan ZhongyuanRuide Biological Products
- Xi'an Huitian Blood Products Co., Ltd.
- Zhenxing Biopharmaceutical & Chemical